Integrating research and development: the emergence of rational drug design in the pharmaceutical industry
Introduction
Pharmacologists typically distinguish two approaches to the development of pharmaceuticals, one termed ‘empirical’, the other ‘rational’, ‘deductive’ or ‘a priori’. The opposition is not, however, about experience or reason being the ultimate source of knowledge, as the terminology could be taken to suggest. Pharmacology, following either of the two methods, is a discipline thoroughly based on experimentation and empirical data. Instead, the distinction is about the role of theoretical understanding in pharmaceutical development. The empirical approach proceeds by testing large numbers of random substances for certain desirable effects in biological test systems or model organisms. Typically, drugs can emerge from this method without their target (receptor, enzyme, and so on), their mode of action or the mechanism of disease being understood. In contrast to this, the rational method usually involves a theoretical understanding of which protein is targeted by the drug, how the drug acts on it, and which mechanisms lead to the desired therapeutic effects.
The rational method, often called ‘rational drug design’, has gradually become more popular in drug development since its first instances in the 1950s. Triggered by a number of impressive successes such as the development of the cholesterol-lowering drug lovastatin or the antihypertensive drug captopril (discussed below) in the 1970s, rational drug design has acquired status as professed methodological ideal in the 1980s (cf. Gambardella, 1995, Ch. 2). This is also evidenced by the awarding of the Nobel Prize for medicine or physiology of 1988 to the pharmacologists Sir James Black, Gertrude B. Elion and George H. Hitchings, three pioneers of rational drug design (Nobel Assembly, 1988).1
In this paper, three case studies of the rational design of cardiovascular drugs—propranolol, captopril, and losartan—will be presented. Their development histories range from the beginnings of rational drug design in the late 1950s to the mid 1990s. Each of these drugs has been developed in the pharmaceutical industry and has introduced a new pharmacological principle into medicine. Up to the present, they (or their direct descendants) are important therapeutics for various cardiovascular conditions. They are, for instance, the prototype drugs for three of the five classes of therapeutics that are most commonly used in the treatment of hypertension (Brown, Quirk, & Kirkpatrick, 2003). Beyond this impact on clinical practice, the development of the drugs also included research that contributed considerably to the scientific understanding of drug action and of physiological and pathological mechanisms. The studied cases thus closely combined two aims of research and development: on the one hand, the practical aim of developing techniques and tools for the practically useful control of and intervention into a system; and on the other hand the epistemic aim of gaining a theoretical understanding of fundamental features of the natural (or artefactual) world. An analysis of the three cases can therefore test a claim that has been put forward by many authors: that integrated practical and epistemic projects are of growing importance for the overall relationship of science and technology.2
In order to make more precise what is meant by ‘practical’ in this claim, epistemic and non-epistemic domains of practice have to be kept distinct. On the one hand, scientific research of course includes a practice (as opposed to theory) in that, for example, experiments are conducted or research technologies developed. However, this practice can be directed entirely or largely at epistemic aims. As such, it can well be (and regularly is) part of basic research, which I roughly understand as research that is directly and primarily targeted at the fundamental scientific understanding of some area.3 On the other hand, technological practices are often concerned with non-epistemic problems, and the development of novel technologies then aims at devices or procedures that are useful for the solution of these problems. The main field of practical application of pharmacological research in this second sense is of course medicine. The main non-epistemic aims of pharmacological research are therefore the alleviation and the cure of diseases (or the economic profits to be drawn from therapeutic usefulness). The claim about the increasing integration of epistemic and practical work refers to practical utility in this second sense that stands in contrast to epistemic purposes.
With respect to pharmacological research and development, a number of options for the relationship of practical and epistemic projects offer themselves. To start with, there are two basic ways to conceive of the practical and epistemic aims as being pursued separately rather than in an integrated manner. Firstly, as in the theoretically uninformed pharmacological empiricism, development can aim at the empirical establishment of useful causal connections between possible drugs and desirable effects without addressing the precise mechanisms that account for the causal dependency. Even though the development of new drugs can disclose phenomena which are also epistemically important, the elucidation of the underlying mechanisms would be left to subsequent research. Secondly, pharmacology could instantiate the familiar linear model of innovation. In this case, there would be a successive or top-down relationship between epistemic and practical work. Research in physiology, biochemistry, pharmacology or pathology would come first and provide fundamental knowledge of physiological and pathological mechanisms. Only subsequently is this knowledge applied and guides the design of drugs. Even though the practical and the epistemic projects can be linked according to both models, they are not combined in one enterprise, but succeed one another both temporally and logically.
The linear model of innovation has found many critics. They have in general objected that many projects in science and technology have both epistemic and practical aims or implications.4 Donald E. Stokes has argued that a type of research that he terms ‘use-inspired basic research’ has been prominent at least since the end of the nineteenth century. He finds in Pasteur a paradigmatic researcher of this type. Such researchers choose their subjects in direct response to practical needs that they aim to solve. However, they also strive for a fundamental understanding of the phenomena (Stokes, 1997). Other authors make out more recent transformations in the combination of epistemic and practical projects. Philippe Larédo and Philippe Mustar, for instance, stress organizational characteristics of what they call ‘basic technological research’. They observe the formation of ‘techno-economic networks’ that include academic and industrial researchers, but also public and financial institutions, and which are engaged both in the development of new products and the gain of scientific knowledge (Larédo & Mustar, 1996; cf. Walsh, 1998). Michael Gibbons and co-authors capture further novel features of research in the context of the development of specific applications under the heading of ‘mode 2 knowledge production’. According to them, such integrated activities often take place in a framework that includes the resources from various disciplines and combines them into a new capability for problem solving. In addition, they see a transformation in the procedures for validating scientific knowledge, since the users of this knowledge (in politics, economy, or society) get included in its establishment (Gibbons, Limoges, Nowotny et al., 1994).
The aim of this paper is to contribute in two major respects to the understanding of the integrated model of innovation. Firstly, it intends to elucidate epistemic characteristics and conditions of combined practical and epistemic projects. The investigation of the three consecutive cases shows that the emergence of the integrated method of rational drug design is closely connected to specific progress both in theory and experimental techniques. The theoretical modeling of the chemical interactions between drugs and targets together with a mechanistic interpretation of experimental test systems enabled the close combination of theory and practice in cycles of mutual advancement.
Secondly, the paper aims to improve the broader understanding of the relation between research and development by elucidating the role of basic research in rational drug design. It will turn out that the integrated epistemic and practical work presupposes input from basic research, while basic results gain practical importance only through additional investigations within the contexts of development. Contrary to the initial impression, the linear and the integrated modes of innovation do therefore not exclude each other. Instead, rational drug design shows how the operation of each can be dependent on the other.
Section snippets
The rational design of propranolol
Propranolol, the first beta-blocker, was developed by a group around James Black at the UK firm Imperial Chemical Industries between 1958 and 1964. The rationale behind the drug development and the main steps leading to propranolol seem straightforward. Propranolol was designed to inhibit the action of adrenaline (also called epinephrine) on the β-adrenoreceptor. Activation of the β-receptor leads, among other things, to an increased pulse rate, which in turn increases the oxygen consumption of
Academic lines of research and their industrial continuation
Captopril is the first antihypertensive drug to inhibit the enzyme ACE (‘angiotensin converting enzyme’), which is an important element of the renin–angiotensin system. The renal enzyme renin catalyzes the conversion of the inactive peptide angiotensinogen into angiotensin I, from which ACE cleaves a dipeptide to produce angiotensin II. By bonding with its receptor, angiotensin II raises the blood pressure, which angiotensin I does not. Hypertension can therefore be treated with substances that
Establishing a therapeutic concept
Losartan is, like captopril, a drug that targets the renin–angiotensin system. It is the first clinically approved angiotensin II receptor antagonist, that is, it blocks the binding of angiotensin II to its natural receptor, thus cutting off the renin–angiotensin mechanism one step later than ACE inhibitors. From its start in the early 1980s, the development program that was eventually successful—conducted by a research group around Pieter Timmermans and Ruth Wexler at DuPont—was directed at a
Closing the cycles of epistemic and practical advancement
From an abstract epistemological perspective, the integration of epistemic and practical projects in rational drug design can be understood on the basis of the dual value both of mechanistic knowledge and of tools for intervention. Knowledge of physiological mechanisms allows for causal explanations why certain phenomena occur (cf., for example, Glennan 2002), but can also point out targets and modes of intervention for practically useful effects. In a similar way, selective substances can be
Acknowledgements
I am grateful to Hans-Jörg Rheinberger, Christina Rouvray, Daniel Sirtes, Leo B. Slater, Friedrich Steinle and Torsten Wilholt for helpful discussions and valuable suggestions on earlier versions of this paper. This research was supported by a grant from the German Research Foundation (DFG).
References (61)
- et al.
Identification of angiotensin II receptor subtypes
Biochemical and Biophysical Research Communications
(1989) - et al.
Development and design of specific inhibitors of angiotensin-converting enzyme
American Journal of Cardiology
(1982) - et al.
High-throughput and virtual screening: Core lead discovery technologies move towards integration
Drug Discovery Today
(2000) - et al.
Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist
European Journal of Pharmacology
(1995) - et al.
Carboxypeptidase A: A protein and an enzyme
Advances in Protein Chemistry
(1971) - et al.
Preliminary biochemical characterization of two angiotensin II receptor subtypes
Biochemical and Biophysical Research Communications
(1989) A study of the adrenotropic receptors
American Journal of Physiology
(1948)Affinity and intrinsic activity in the theory of competitive inhibition
Archives internationales de pharmacodynamie et de thérapie
(1954)The predictive value of animal tests in relation to drugs affecting the cardiovascular system in man
Ahlquist and the development of beta-adrenoreceptor antagonists
Postgraduate Medical Journal
(1976)
Drugs from emasculated hormones: The principle of syntopic antagonism
Science
A personal view of pharmacology
Annual Review of Pharmacology and Toxicology
Eplerenone
Nature Reviews Drug Discovery
Science: The endless frontier
Binding of the by-product analog benzylsuccinic acid by carboxypeptidase A
Biochemistry
Autonomic neuro-effector systems
General pharmacology
Design of potent competitive inhibitors of angiotensin-converting enzyme. Carboxyalkanoyl and mercaptoalkanoyl amino acids
Biochemistry
Angiotensin converting enzyme inhibitors: Evolution of a new class of antihypertensive drugs
History of the design of captopril and related inhibitors of angiotensin converting enzyme
Hypertension
Inhibition of angiotensin-converting enzyme by analogs of peptides from Bothrops jararaca venom
Experientia
The endless transition: A ‘triple helix’ of university–industry–government relations
Minerva
Isolation of bradykinin-potentiating peptides from Bothrops jararaca venom
Biochemistry
Activity of various fractions of bradykinin potentiating factor against angiotensin I converting enzyme
Nature
Potentiation of bradykinin and eledoisin by BPF (bradykinin potentiating factor) from Bothrops jararaca venom
Experientia
Side effects associated with inhibitors of angiotensin-converting enzyme
Science and innovation. The US pharmaceutical industry during the 1980s
The new production of knowledge. The dynamics of science and research in contemporary societies
Rethinking mechanistic explanation
Philosophy of Science
Cited by (25)
Current trends in computer aided drug design and a highlight of drugs discovered via computational techniques: A review
2021, European Journal of Medicinal ChemistryDivergence and convergence of commercial and scientific priorities in drug development: The case of Zelmid, the first SSRI antidepressant
2015, Social Science and MedicineCitation Excerpt :It is important to point out that Astra was not alone in pursuing the new paradigm of mechanism-based drug discovery in the 1960s. Rather, as Ross explained to me, prominent psychopharmacology researchers, such as Axelrod and Carlsson, had advanced such ideas beginning in the latter half of the 1950s and similar ideas were informing research in other disease areas (Adam, 2005). Nonetheless, as late as the early 1980s, some major pharmaceutical companies still relied on large synthesis and screening programs.
Intervention, causal reasoning, and the neurobiology of mental disorders: Pharmacological drugs as experimental instruments
2012, Studies in History and Philosophy of Science Part C :Studies in History and Philosophy of Biological and Biomedical SciencesCitation Excerpt :The formulation of the revised dopamine hypothesis was also facilitated by experimental knowledge gained with other pharmacological drugs (e.g., stimulant drugs, hallucinogen drugs), which has implicated the importance of other neurotransmitters—such as glutamate and serotonin—in the neurobiology of schizophrenia. The way in which pharmacological research facilitates the refinement and revision of neurobiological theories of schizophrenia highlights the dynamic and interactive relationship between clinical contexts (applied science) and research contexts (pure science) in psychiatry (cf. Adam, 2005). While pharmacological research is motivated primarily to design better pharmacological treatments for schizophrenia in clinical contexts, the drugs that are developed often play a crucial role in assisting researchers to expand and revise existing neurobiological theories of mental disorders in research contexts.
The evolution of angiotensin blockade in the management of cardiovascular disease
2010, Canadian Journal of CardiologyMedicinal Chemistry Assignment Requiring Undergraduate Pharmacy Students To Utilize Free Web-Based Resources
2023, Journal of Chemical Education